MCID: ADL008
MIFTS: 35

Adult Oligodendroglioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adult Oligodendroglioma

MalaCards integrated aliases for Adult Oligodendroglioma:

Name: Adult Oligodendroglioma 12 15
Adult Brain Oligodendroglioma 12 70
Grade Ii Adult Oligodendroglial Tumor 12
Oligodendroglioma, Adult 70

Classifications:



External Ids:

Disease Ontology 12 DOID:3186
MeSH 44 D009837
NCIt 50 C4014 C9376
UMLS 70 C0279070 C1332190

Summaries for Adult Oligodendroglioma

MalaCards based summary : Adult Oligodendroglioma, also known as adult brain oligodendroglioma, is related to oligodendroglioma and cerebellum cancer, and has symptoms including seizures and headache. An important gene associated with Adult Oligodendroglioma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Cell cycle_Chromosome condensation in prometaphase and Central carbon metabolism in cancer. The drugs Temozolomide and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone.

Related Diseases for Adult Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Adult Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 28.7 OLIG2 IDH2 IDH1 FUBP1 FGFR1
2 cerebellum cancer 10.2 KIAA1549 IDH1
3 juvenile astrocytoma 10.2 KIAA1549 IDH1
4 malignant giant cell tumor 10.2 H3-3B H3-3A
5 gliofibroma 10.2 KIAA1549 IDH1
6 bone giant cell sarcoma 10.2 H3-3B H3-3A
7 telangiectatic osteogenic sarcoma 10.2 H3-3B H3-3A
8 clear cell ependymoma 10.2 OLIG2 IDH1
9 benign ependymoma 10.2 KIAA1549 IDH1
10 optic nerve neoplasm 10.2 OLIG2 KIAA1549
11 enchondroma 10.2 IDH2 IDH1
12 cytogenetically normal acute myeloid leukemia 10.2 IDH2 IDH1
13 colon leiomyoma 10.2 H3-3B H3-3A
14 intracranial chondrosarcoma 10.2 IDH2 IDH1
15 periosteal chondrosarcoma 10.2 IDH2 IDH1
16 supratentorial primitive neuroectodermal tumor 10.2 OLIG2 IDH1
17 juxtacortical chondroma 10.2 IDH2 IDH1
18 gemistocytic astrocytoma 10.2 IDH2 IDH1
19 cerebral ventricle cancer 10.2 OLIG2 IDH1
20 mixed oligodendroglioma-astrocytoma 10.2 IDH2 IDH1
21 thalamic neoplasm 10.2 MYBL1 KIAA1549
22 cerebrum cancer 10.2 OLIG2 IDH1
23 low grade glioma 10.2 IDH2 IDH1
24 spinal cord oligodendroglioma 10.1 IDH1 FGFR1
25 bone benign neoplasm 10.1 H3-3B H3-3A
26 anaplastic oligodendroglioma 10.1 OLIG2 IDH2
27 spindle cell hemangioma 10.1 IDH2 IDH1
28 alpha thalassemia-x-linked intellectual disability syndrome 10.1 H3-3B H3-3A
29 bone giant cell tumor 10.1 H3-3B H3-3A
30 high grade ependymoma 10.1 KIAA1549 IDH1 H3-3A
31 childhood brain stem glioma 10.1 IDH1 H3-3B H3-3A
32 diencephalic neoplasm 10.1 MYBL1 KIAA1549
33 brain stem cancer 10.1 IDH1 H3-3B H3-3A
34 supratentorial cancer 10.1 OLIG2 KIAA1549 IDH1
35 pilocytic astrocytoma of cerebellum 10.1 PASD1 KIAA1549 IDH1
36 cerebellar astrocytoma 10.1 PASD1 KIAA1549 IDH1
37 d-2-hydroxyglutaric aciduria 1 10.1 IDH2 IDH1
38 2-hydroxyglutaric aciduria 10.1 IDH2 IDH1
39 l-2-hydroxyglutaric aciduria 10.0 IDH2 IDH1
40 multiple enchondromatosis, maffucci type 10.0 IDH2 IDH1 H3-3B
41 alpha-thalassemia 10.0 IDH1 H3-3B H3-3A
42 benign giant cell tumor 10.0 H3-3B H3-3A
43 clear cell chondrosarcoma 10.0 IDH2 H3-3B H3-3A
44 enchondromatosis, multiple, ollier type 10.0 IDH2 IDH1
45 pediatric meningioma 10.0 KIAA1549 FUBP1
46 temporal lobe neoplasm 10.0 IDH1 FUBP1
47 glioma susceptibility 1 10.0 IDH2 IDH1 H3-3A
48 chondroblastoma 10.0 H3-3B H3-3A FGFR1
49 spinal cord astrocytoma 9.9 KIAA1549 IDH1 H3-3B H3-3A
50 connective tissue benign neoplasm 9.9 H3-3B H3-3A

Graphical network of the top 20 diseases related to Adult Oligodendroglioma:



Diseases related to Adult Oligodendroglioma

Symptoms & Phenotypes for Adult Oligodendroglioma

UMLS symptoms related to Adult Oligodendroglioma:


seizures; headache

Drugs & Therapeutics for Adult Oligodendroglioma

Drugs for Adult Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Donepezil Approved Phase 3 120014-06-4 3152
4
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
5
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
6
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
7 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
8 Tubulin Modulators Phase 2, Phase 3
9 Antimitotic Agents Phase 2, Phase 3
10 Alkylating Agents Phase 3
11 Analgesics Phase 3
12 Nootropic Agents Phase 3
13 Cola Phase 3
14 Narcotics Phase 3
15 Anesthetics Phase 3
16 Liver Extracts Phase 3
17 Anesthetics, Intravenous Phase 3
18 Anesthetics, General Phase 3
19 Analgesics, Opioid Phase 3
20 Cholinesterase Inhibitors Phase 3
21 Neurotransmitter Agents Phase 3
22 Cholinergic Agents Phase 3
23
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
24
Bevacizumab Approved, Investigational Phase 2 216974-75-3
25
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
26
Levetiracetam Approved Phase 2 102767-28-2 441341
27
Pregabalin Approved, Investigational Phase 2 148553-50-8 5486971
28
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
29
Sodium citrate Approved, Investigational Phase 2 68-04-2
30
Tamoxifen Approved Phase 2 10540-29-1 2733526
31
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
32
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
33
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
34
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
35
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
36
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
37
Lenograstim Approved, Investigational Phase 2 135968-09-1
38
Etoposide Approved Phase 2 33419-42-0 36462
39
Busulfan Approved, Investigational Phase 2 55-98-1 2478
40
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
41
Iodine Approved, Investigational Phase 2 7553-56-2 807
42
Acetaminophen Approved Phase 2 103-90-2 1983
43
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
44
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
46
Promethazine Approved, Investigational Phase 2 60-87-7 4927
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
48
Cadexomer iodine Experimental Phase 2 94820-09-4
49 Anti-Infective Agents Phase 2
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
5 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
6 A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas Unknown status NCT00114140 Phase 2 Temozolomide
7 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
8 Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial Completed NCT01164189 Phase 2 Temozolomide
9 Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma Completed NCT00892177 Phase 2 dasatinib
10 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
11 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
12 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
13 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
14 Immunotherapy for Malignant Glioma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy Completed NCT00004024 Phase 2
15 Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy Completed NCT00003304 Phase 2 temozolomide
16 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
17 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
18 CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
19 First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial Completed NCT00003731 Phase 2 temozolomide
20 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
21 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
22 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
23 A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma Completed NCT00313729 Phase 2 temozolomide
24 Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal Completed NCT00003466 Phase 2 temozolomide
25 Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
26 A Phase II Trial of Irinotecan in Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
27 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
28 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
29 Phase I/II Trial of Pyrazoloacridine and Carboplatin in Patients With Recurrent Glioma Completed NCT00005976 Phase 2 carboplatin;pyrazoloacridine
30 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
31 A Single-Arm, Open-label, Phase II Study Evaluating the Efficacy and Safety of Abemaciclib in Patients With Recurrent Oligodendroglioma Recruiting NCT03969706 Phase 2 Abemaciclib 200 MG
32 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
33 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Oligodendroglioma Terminated NCT00003472 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
34 Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study) Withdrawn NCT00005083 Phase 2
35 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
36 Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
37 Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
38 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
39 A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
40 Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones Completed NCT00730613 Phase 1
41 A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors Completed NCT00544284 Phase 1 bortezomib;temozolomide
42 Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms Completed NCT00019578 Phase 1
43 Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma Completed NCT00004892 Phase 1 O6-benzylguanine;polifeprosan 20 with carmustine implant
44 Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
45 Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration Completed NCT00401024 Phase 1 imatinib mesylate
46 A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
47 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
48 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
49 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
50 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat

Search NIH Clinical Center for Adult Oligodendroglioma

Genetic Tests for Adult Oligodendroglioma

Anatomical Context for Adult Oligodendroglioma

MalaCards organs/tissues related to Adult Oligodendroglioma:

40
Brain, Spinal Cord, Bone, Cerebellum, Colon, Liver, Myeloid

Publications for Adult Oligodendroglioma

Articles related to Adult Oligodendroglioma:

# Title Authors PMID Year
1
Rare occurrence of IDH2 mutation in adolescent oligodendroglioma with 1p/19q co-deletion: a case report. 61
32296936 2020
2
Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis. 61
29902567 2018
3
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. 61
29131101 2018
4
Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma. 61
27862886 2017
5
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. 61
21069360 2011

Variations for Adult Oligodendroglioma

Expression for Adult Oligodendroglioma

Search GEO for disease gene expression data for Adult Oligodendroglioma.

Pathways for Adult Oligodendroglioma

Pathways related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 H3-3B H3-3A
2 10.64 IDH2 IDH1 FGFR1
3
Show member pathways
10.07 IDH2 IDH1

GO Terms for Adult Oligodendroglioma

Cellular components related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Barr body GO:0001740 8.62 H3-3B H3-3A

Biological processes related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 oogenesis GO:0048477 9.56 H3-3B H3-3A
2 embryo implantation GO:0007566 9.55 H3-3B H3-3A
3 chromatin silencing at rDNA GO:0000183 9.54 H3-3B H3-3A
4 tricarboxylic acid cycle GO:0006099 9.52 IDH2 IDH1
5 nucleus organization GO:0006997 9.51 H3-3B H3-3A
6 telomere organization GO:0032200 9.49 H3-3B H3-3A
7 DNA replication-independent nucleosome assembly GO:0006336 9.48 H3-3B H3-3A
8 muscle cell differentiation GO:0042692 9.46 H3-3B H3-3A
9 2-oxoglutarate metabolic process GO:0006103 9.43 IDH2 IDH1
10 NADP metabolic process GO:0006739 9.4 IDH2 IDH1
11 isocitrate metabolic process GO:0006102 9.37 IDH2 IDH1
12 pericentric heterochromatin assembly GO:0031508 9.32 H3-3B H3-3A
13 regulation of centromere complex assembly GO:0090230 9.26 H3-3B H3-3A
14 negative regulation of chromosome condensation GO:1902340 9.16 H3-3B H3-3A
15 telomeric heterochromatin assembly GO:0031509 8.96 H3-3B H3-3A
16 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 PASD1 OLIG2 MYBL1 H3-3B H3-3A
2 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.4 IDH2 IDH1
3 nucleosomal DNA binding GO:0031492 9.37 H3-3B H3-3A
4 NAD binding GO:0051287 9.32 IDH2 IDH1
5 RNA polymerase II core promoter sequence-specific DNA binding GO:0000979 9.16 H3-3B H3-3A
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
7 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Adult Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....